Nebivolol

證據等級: L5

預測適應症: 5 個

Nebivolol: From Hypertension to Malignant Hypertensive Renal Disease

One-Sentence Summary

Nebivolol is a third-generation, highly selective β1-adrenergic receptor blocker with unique nitric oxide (NO)-mediated vasodilatory properties, widely used internationally for the treatment of hypertension and heart failure. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, with 0 clinical trials and 0 publications specifically supporting this indication. Evidence is currently limited to mechanistic inference, placing this prediction at the research hypothesis stage.

Quick Overview

Item	Content
Original Indication	Hypertension / Heart failure (international standard; not marketed in India)
Predicted New Indication	Malignant Hypertensive Renal Disease
TxGNN Prediction Score	99.42%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on publicly known pharmacology, Nebivolol is a third-generation β1-selective adrenergic receptor blocker with a dual mechanism that sets it apart from older beta-blockers: it reduces cardiac output and systemic blood pressure through high-affinity β1 blockade, and additionally stimulates nitric oxide (NO) release via the L-arginine/eNOS pathway, producing arterial vasodilation that conventional beta-blockers do not provide.

Malignant hypertensive renal disease is a severe complication of uncontrolled hypertension characterised by grade III–IV hypertensive retinopathy, rapidly escalating blood pressure, and acute kidney injury secondary to renal arteriolar fibrinoid necrosis. β1 blockade reduces cardiac output and suppresses renin secretion, directly lowering the sustained systemic pressure responsible for renal microvasculature injury. Nebivolol’s NO-mediated vasodilatory effect may additionally preserve intrarenal perfusion during pressure reduction, offering a potential renoprotective advantage over older beta-blockers that simply reduce output without vasodilation.

It is important to note, however, that in current clinical practice malignant hypertension is first managed with intravenous agents (labetalol, sodium nitroprusside, nicardipine) for rapid blood pressure control; oral beta-blockers occupy an adjunctive, maintenance role. No direct clinical trial data exist for Nebivolol specifically in this severe hypertensive subtype, and the mechanistic hypothesis — while scientifically coherent — remains unvalidated.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Note: A PubMed search for Nebivolol and the rank-3 prediction (pulmonary hypertension owing to lung disease/hypoxia) returned 20 results; however, on review these papers address general hypoxia biology (tumour hypoxia, neurodegeneration, tissue repair) and contain no data on Nebivolol in pulmonary hypertension. They are not clinically relevant to any repurposing hypothesis in this pack.

India Market Information

Nebivolol is currently not marketed in India. There are no registered products, active licences, or locally approved indications on record. Any repurposing pathway would require a full market-entry regulatory strategy in addition to clinical development.

Safety Considerations

Drug Interactions — 174 documented interactions (selected key interactions shown):

Interacting Drug	Level	Relevance
Epinephrine	Moderate	Risk of acute hypertensive rebound and attenuated bronchodilation
Dexamethasone / Betamethasone / Budesonide / Triamcinolone / Hydrocortisone	Moderate	Corticosteroids may blunt the antihypertensive effect
Canagliflozin / Dapagliflozin / Chlorpropamide	Moderate	Beta-blockade can mask hypoglycaemia warning signs
Bupropion	Moderate	Possible potentiation of cardiovascular adrenergic effects
Morphine	Moderate	Additive hypotensive effect
Atropine / Hyoscyamine / Glycopyrronium / Dicyclomine	Moderate	Anticholinergics may counteract beta-blocker-induced bradycardia
Lorcaserin	Moderate	Potential serotonergic/cardiovascular interaction
Calcium Phosphate / Calcium acetate	Moderate	Divalent cations may reduce oral absorption
Acetylsalicylic acid	Minor	Minimal pharmacodynamic interaction
Magnesium oxide	Minor	Possible slight reduction in absorption

Package insert warnings and contraindications are not currently available in this evidence pack. Please refer to the full prescribing information for complete safety details before any clinical application.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the mechanistic basis is scientifically plausible — β1 blockade reduces renal perfusion pressure and Nebivolol’s NO pathway may confer additional renoprotection — there is a complete absence of direct clinical trial evidence or disease-specific literature for malignant hypertensive renal disease. In current practice, this condition is managed with intravenous agents, which significantly limits the immediate repurposing pathway for an oral agent.

To proceed, the following is needed:

MOA confirmation: Retrieve full DrugBank entry to formally document the β1/eNOS/NO mechanism and its renal haemodynamic implications
Safety baseline: Download and parse the TFDA (or EMA/FDA) prescribing information to populate warnings and contraindications (currently blocking S1 safety assessment)
Targeted literature review: Commission a systematic search for Nebivolol + renal protection / hypertensive nephropathy, and for class-level evidence (third-generation beta-blockers + malignant hypertension)
Preclinical data gap: Identify whether any animal or in vitro studies have examined Nebivolol in malignant or renovascular hypertension models
India regulatory pathway: Since Nebivolol is not marketed in India, map the NDA/IND route and assess whether existing foreign approvals (EU, US) can support a bridging strategy
Dose-adjustment considerations: Evaluate PK data in the context of renal impairment, as target patients may have significantly compromised GFR
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.